ALK’s peanut tablet shown to be safe and tolerable across multiple doses.Development now advances to phase II for dose finding and efficacy.

Receptors such as EGFR, HER2, MET and ALK interface with common downstream signaling pathways and 'addiction switching' can occur, either by the inhibition of one receptor triggering a switch to ...

The peanut tablet spearheads ALK's future portfolio in food allergy, which also spans novel concepts in pre-clinical development targeting other pathways and indications. ALK-Abelló A/S For further ...